Vaxcyte, Inc. Common Stock PCVX
Analyst Ratings
- Consensus
- Buy — 4 Buy · 0 Hold · 0 Sell (4 analysts)
- Avg. Price Target
- $116.50 (+74.7% upside)
Key Stats
- Today's Range
- $63.90 – $73.39
- 50-Day Range
- $52.47 – $90.75
- 52-Week Range
- $30.81 – $90.75
- Volume
- 10.16 million shs
- Average Volume
- 2.11 million shs
- Market Cap
- $10.98 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 3.98
- Price / Sales
- —
Short Interest
- Short Interest
- 0.13%
- Days to Cover
- 1.21
About Vaxcyte, Inc. Common Stock
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
Related Stocks
Compare head-to-head: PCVX vs AMGN·PCVX vs MRNA·PCVX vs TWST·PCVX vs HALO
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.